Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation ...

Cashin, MD, chief medical officer, Novotech, shares why clear communication, strong leadership, and cultural alignment are essential to building effective partnerships between CROs, sponsors, and ...

Peter Ronco, CEO, Emmes, explains how the company is investing in transparent goal setting, comprehensive education, and ...

In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of ...

As wearable ECG technology advances, cardiac safety studies in clinical trials are evolving to capture richer, continuous ...

Cashin, MD, chief operating officer, Novotech, explains why seamless collaboration between CROs and sponsors is critical to advancing clinical trials, and reflects on Novotech’s recognition as ...

In this Q&A, Megan Bailey, EVP and president of central laboratories and international, Labcorp, discusses how central labs ...

In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of ...

Balancing the emerging benefits of AI in pharmacovigilance with new responsibilities and demands from regulators in enhancing ...

Recent analysis explores AI's momentum in drug development, showcasing rapid adoption and significant time savings, despite ...

Joint Clinical Assessment is now a parallel requirement under HTAR. Health technology developers must prepare for a JCA ...

Peter Ronco, CEO, Emmes, explains why AI in clinical development still needs human oversight despite widespread hype.